What We Heard in Denver — and What P4HR Changed Because of It

The Denver roundtable did what a serious policy discussion should do: it challenged assumptions. P4HR listened. We have already strengthened AEROPath, rebuilt HIMS Voices, and sharpened the question at the center of reform: when does recovery support end and indefinite government surveillance begin?

DENVER — We did not hold the P4HR roundtable at the 2026 HIMS Seminar to hear only from people who already agreed with us.

We wanted the difficult questions.

We got them.

Participants challenged our survey methodology, questioned whether an alternative pathway could be manipulated by pilots or overly accommodating clinicians, defended the value of long-term accountability, emphasized the importance of multiple observers in recovery, and warned against weakening a program they believe has saved lives and restored careers.

Those concerns deserve a serious answer.

They also exposed something important: the real disagreement is no longer simply whether recovery matters. Everyone in the room appeared to agree that safety, treatment and meaningful recovery matter.

The harder question is what follows from that agreement.

Safety is non-negotiable. Recovery can be lifelong. Government surveillance should not be lifelong merely because recovery is.

The Strongest Argument We Heard

The strongest defense of the existing HIMS model was not that every rule is perfect.

It was that recovery from substance-use disorder can require long-term accountability and that a pilot returning to safety-sensitive work may benefit from meetings, sponsorship, peer contact, testing, clinical follow-up and multiple people watching for signs of deterioration.

That argument cannot simply be dismissed.

Some people genuinely benefit from long-term structured recovery support. Some may need intensive monitoring for significant periods. New safety-relevant evidence may justify increased oversight even after a period of stability.

P4HR does not oppose any of that.

But Denver helped crystallize a distinction that must be made more clearly than it has been in the past.

Those concepts overlap. They are not interchangeable.

A pilot may choose to remain in recovery meetings for life. That does not by itself prove that the federal government must require the same intensity of testing and surveillance for life.

If enhanced FAA oversight remains necessary, it should continue.

But the government should be able to explain why this person, at this time, still presents a materially elevated aviation-safety risk and why a less restrictive alternative would not adequately address it.

Denver Exposed a Weakness in AEROPath. We Fixed It.

During the roundtable, AEROPath was vulnerable to an easy caricature: that a pilot could simply choose a friendly doctor, construct a favorable team and eventually decide that monitoring was no longer necessary.

That is not the pathway P4HR intends to build.

So we rewrote it.

The updated AEROPath framework now includes:

• FAA-recognized provider qualification standards rather than unrestricted provider choice.
• Conflict-of-interest safeguards applicable to independent clinicians, airline programs and HIMS participants alike.
• Individualized risk assessment rather than a predetermined universal monitoring period.
• True random testing and defensible laboratory procedures where testing is medically and aeromedically warranted.
• Clear safety triggers allowing monitoring to increase again when new evidence demonstrates increased risk.
• Published step-down criteria so an airman knows what progress actually requires.
• A genuine pathway to unrestricted certification when enhanced oversight is no longer supported by current evidence.

We also saw another risk after Denver: in trying to reassure skeptics that AEROPath would not weaken safety, we could accidentally give the FAA too much unbounded discretion and recreate the current problem under a new name.

So we strengthened the other side of the architecture too.

FAA Authority Must Have Limits

The updated AEROPath standard now states:

Enhanced monitoring may continue only when supported by specific, current, individualized, and medically competent evidence demonstrating a materially elevated aviation-safety risk that cannot reasonably be addressed through a less restrictive alternative.

That language matters.

After an airman satisfies published milestones, the burden should no longer remain indefinitely on the airman to prove a negative. Continued enhanced monitoring should require the FAA to identify current evidence supporting continued restriction.

The revised model also includes:

• defined review dates rather than indefinite status quo by default;
• written reasons identifying the evidence and standard relied upon;
• a prohibition on moving the goalposts absent genuinely new safety-relevant evidence;
• the least-restrictive alternative principle;
• meaningful independent review outside the original decisional chain;
• expedited remedies when the FAA ignores deadlines or departs from published standards;
• access to the material record used in the decision;
• the right to challenge disputed testing or laboratory evidence; and
• protection against retaliation for exercising review rights.

We have also incorporated an explicit Airman Bill of Rights into the AEROPath architecture.

This is what due process looks like when it is translated from a principle into an operating system.

The Room Was Right to Challenge HIMS Voices

Our original HIMS Voices survey has produced important firsthand accounts, but Denver exposed a real methodological weakness.

When participants asked how representative the responses were, how many respondents had returned to flight, how many had experienced relapse or return to use, and whether the survey disproportionately attracted people with negative experiences, the correct answer was not to become defensive.

The correct answer was to build a better instrument.

We did.

HIMS Voices 2.0 is now live.

The rebuilt survey is designed to capture much more than dissatisfaction. It asks about outcomes and context, including:

• firsthand HIMS participation and pathway;
• diagnosis and severity context;
• treatment intensity;
• monitoring duration and testing;
• return-to-use or relapse history;
• return-to-flight and current FAA medical status;
• time grounded, direct costs and lost income;
• whether written criteria and meaningful review were available;
• testing disputes and how they were handled;
• overall fairness, transparency, trust, dignity, coercion and clinical individualization; and
• optional demographic and professional characteristics that allow us to understand who responded without collecting unnecessary identifying information.

Just as importantly, HIMS Voices 2.0 explicitly welcomes positive, neutral, mixed and negative experiences.

We want to hear from pilots who believe HIMS worked exceptionally well for them.

If the program helped save a life, restore a family or return a pilot safely to the flight deck, that belongs in the data too.

And we are being clearer about what the survey can and cannot prove. HIMS Voices is an opt-in, non-probability survey. It is a structured dataset of respondent experiences and outcomes—not a claim that every percentage can automatically be generalized to every HIMS participant in the country.

That transparency makes the project stronger, not weaker.

Some of the Criticism Actually Strengthened the Case for Reform

Several roundtable participants raised concerns about clinician quality, personal relationships between providers and pilots, inconsistent professional judgment, testing interpretation and the possibility that individuals may try to game monitoring.

Those concerns are legitimate.

But they do not establish that the status quo should remain untouched.

They establish the need for national qualification standards, conflict rules, auditability, transparent testing procedures and independent review.

If inconsistent judgment and conflicts can occur within the existing HIMS ecosystem, institutional familiarity cannot itself be the safety standard.

The standard has to be evidence.

The Most Important Thing Denver Could Not Answer: Where Is the Outcome Data?

The roundtable repeatedly returned to questions that neither side could answer with the level of national data a program this consequential should have available.

Among them:

• What are relapse or recurrence rates at different stages of monitoring?
• What is the incremental safety benefit of years three, four, five and beyond?
• How long do comparable pilots remain in enhanced monitoring?
• How many eventually receive unrestricted certification?
• Which interventions actually predict better aviation outcomes?
• Are more frequent tests producing measurable safety benefits in long-stable individuals?
• How do outcomes differ by diagnosis, severity, treatment history and length of demonstrated stability?
• What are the consequences when a laboratory result is disputed or later shown to be unreliable?

Those are not anti-HIMS questions.

They are the questions an evidence-based safety program should want answered.

If prolonged monitoring produces a measurable safety benefit, show it.

If a particular intervention materially reduces risk, preserve it.

If another requirement adds burden without measurable benefit, modernize it.

What Comes Next

Denver did not make P4HR less committed to reform.

It made the reform agenda more precise.

Our next phase will include three priorities.

A Better Question Than “Are You For or Against HIMS?”

Denver reinforced our belief that the aviation community is asking the wrong binary question when it asks people to choose between supporting HIMS and supporting reform.

The better question is:

What standards should any aviation medical monitoring program have to satisfy before the government can impose, continue or escalate restrictions on an airman?

P4HR's answer is becoming increasingly clear.

Qualified medicine.

Current individualized evidence.

Proportionality.

Transparent standards.

Reliable testing.

Written reasons.

Independent review.

Measurable milestones.

And a real endpoint when enhanced oversight is no longer medically justified.

That standard should apply to HIMS. It should apply to AEROPath. And it should apply to whatever comes next.